Form 4: ANAB CMO Sells Shares for Tax After RSU Vesting

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, reported the vesting of 8,525 restricted stock units and a subsequent sale of 3,650 shares to cover tax obligations.

Summary

• Paul F. Lizzul, Chief Medical Officer of AnaptysBio, Inc., reported transactions related to his beneficial ownership.
• On January 7, 2026, 8,525 restricted stock units (RSUs) vested and settled, converting into 8,525 shares of common stock.
• Following this, on January 8, 2026, Mr. Lizzul sold 3,650 shares of common stock at a price of $44.71 per share.
• This sale was explicitly stated as a "sell to cover" transaction, intended solely to satisfy tax withholding obligations arising from the RSU vesting, and was not a discretionary sale.
• After these transactions, Mr. Lizzul beneficially owns 42,088 shares of AnaptysBio common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The RSU vesting is a positive sign of executive compensation and retention, while the subsequent sale is a non-discretionary tax-related event, which is standard practice and not indicative of negative sentiment from the executive.

Positives

• The vesting of 8,525 restricted stock units indicates continued compensation and retention of a key executive.
• The "sell to cover" transaction is a standard practice for RSU vesting, indicating a non-discretionary sale rather than a lack of confidence in the company.

Negatives

• A reduction in the Chief Medical Officer's direct beneficial ownership by 3,650 shares, even if for tax purposes.

Risks

• Potential for misinterpretation of the share sale as a discretionary action, which could negatively impact investor sentiment if not properly understood as a tax-related transaction.

Future Outlook

The remaining 25,575 derivative securities (Restricted Stock Units) will continue to vest as to 25% of the total annually commencing on January 7, 2026, subject to the reporting person's continued provision of service to the Issuer.

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies where executives receive equity awards. It does not provide specific insights into AnaptysBio's industry position or trends beyond standard compensation practices.

Comparison to Industry Standards

• "Sell to cover" transactions are a standard and widely accepted mechanism for executives to manage tax liabilities arising from equity compensation across all industries. There are no specific comparable companies, projects, or results mentioned in this filing to benchmark against.

Stakeholder Impact

• Shareholders: The reduction in direct beneficial ownership by a key executive, even for tax purposes, could be viewed neutrally or slightly negatively if misinterpreted. However, the underlying RSU vesting is a positive sign of executive alignment.
• Employees: The vesting of RSUs is a standard form of equity compensation, which can positively impact employee morale and retention, especially for executives.

Next Steps

• Remaining 25,575 Restricted Stock Units (RSUs) will continue to vest annually at 25% commencing on January 7, 2026, subject to the reporting person's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary insider transaction related to executive compensation. The vesting of RSUs is a positive event for executive retention, and the subsequent "sell to cover" is a standard tax management practice. It does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

AnaptysBio, ANAB, Paul F. Lizzul, Chief Medical Officer, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, sell to cover, executive compensation, stock sale